Loading...
Market
Story
Novo Nordisk's Semaglutide 7.2 mg Achieves 20.7% Weight Loss in STEP UP Trial, 18.7% Overall in 1,407 Participants
Jan 17, 2025, 12:20 PM
Novo Nordisk A/S announced that its STEP UP trial for semaglutide 7.2 mg demonstrated a primary endpoint achievement with a statistically significant weight loss of 20.7% after 72 weeks of treatment. This result was achieved with treatment adherence among participants, who averaged a weight loss of 20.7%. In cases of broader treatment considerations, the average weight loss was reported at 18.7%. The trial involved 1,407 participants with obesity. In comparison, semaglutide 2.4 mg resulted in a weight loss of 17.5%, while placebo participants lost an average of 2.4%. The STEP UP trial results are positioned against Eli Lilly's Zepbound, which recorded a 23% weight loss over 176 weeks, according to data from August 2024.
View original story
Similar markets
No • 50%
Yes • 50%
Yes • 50%
No • 50%
UnitedHealth Group • 25%
Other • 25%
Aetna • 25%
Anthem • 25%
Less than 20% weight loss • 25%
More than 24% weight loss • 25%
22% to 24% weight loss • 25%
20% to 22% weight loss • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Alzheimer's Disease • 25%
Other • 25%
Metabolic Liver Dysfunction • 25%
Obstructive Sleep Apnea • 25%
Addiction Treatment • 25%
Other • 25%
Diabetic Macular Edema • 25%
Metabolic Liver Dysfunction • 25%
Novo Nordisk • 25%
Other • 25%
Viking Therapeutics • 25%
Eli Lilly • 25%
Brain disorders • 25%
Kidney disease • 25%
Stroke • 25%
Heart disease • 25%
No • 50%
Yes • 50%
Viking Therapeutics • 25%
Eli Lilly • 25%
Other • 25%
Pfizer • 25%